Eli Lilly launches Lormalzi for early Alzheimer’s treatment in India
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Subscribe To Our Newsletter & Stay Updated